Recon: EU eyes new rules governing AI; Bluebird’s newly approved sickle cell gene therapy priced at $2.2M
ReconJason Scott
Biologics/ biosimilars/ vaccinesBiotechnologyEuropeGlobalMedical DevicesPharmaceuticalsRegulatory Intelligence/PolicyUnited States